1. Asthma Medication Ratio Phenotypes in Elderly Women
Sébastien Chanoine, PharmD, Isabelle Pin, MD, Margaux Sanchez, PhD, Sofia Temam, PhD, Christophe Pison, MD, Nicole Le Moual, PhD, Gianluca Severi, PhD, Marie-Christine Boutron-Ruault, PhD, Agnès Fournier, PhD, Jean Bousquet, MD, Pierrick Bedouch, PharmD, Raphaëlle Varraso, PhD, Valérie Siroux, PhD 
The Journal of Allergy and Clinical Immunology: In Practice 
DOI: /j.jaip
Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2. Figure 1
Study population flowchart and study aims. “Inconsistent” defined women who did not report to have ever asthma in the Asthma-E3N questionnaire. AIM 1, to characterize the level of the controller-to-total asthma medication ratio in elderly women and identify its determinants (n = 899); AIM 2, to prospectively assess the relationship of the short-term (12 months) ratio with the subsequent risk of poor asthma-related outcomes; and AIM 3, to prospectively investigate the relationship of distinct profiles of the long-term fluctuations of the ratio with asthma-related outcomes (n = 4,328).
The Journal of Allergy and Clinical Immunology: In Practice DOI: ( /j.jaip )
Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3. Figure 2
Predictive ability of the controller-to-total asthma medication ratio below 0.5 (odds ratio with 95% CI) for poor asthma-related outcomes (uncontrolled asthma, asthma attacks, and asthma exacerbations) among women regularly exposed to asthma maintenance therapy over the previous 12 months (n = 899): A, whole population; B, women with a high asthma maintenance therapy level (steps 4 and 5 according to the GINA classification; n = 555 over the 2 years that preceded the Asthma-E3N questionnaire); and C, women with a low asthma maintenance therapy level (steps 1 to 3 according to the GINA classification; n = 344 over the 2 years that preceded the Asthma-E3N questionnaire). Adjusted models included age, active smoking, ever rhinitis, and body mass index. CI, Confidence interval; E3N, Etude Epidémiologique auprès de femmes de la Mutuelle Générale de l'Education Nationale; GINA, Global Initiative for Asthma; OR, odds ratio.
The Journal of Allergy and Clinical Immunology: In Practice DOI: ( /j.jaip )
Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4. Figure 3
Description of the fluctuations of the controller-to-total asthma medication ratio over an 8-year period, defined by latent class analysis among women with ever asthma from the Asthma-E3N study (n = 4,328): A, never regularly asthma maintenance therapy (labeled “Never regular treatment”); B, persistent controller-to-total asthma medication ratio ≥0.5 (labeled “Persistent high ratio”); C, increased controller-to-total asthma medication ratio from <0.5 to ≥0.5 (labeled “Increasing ratio”); D, initiation of asthma maintenance therapy with a controller-to-total asthma medication ratio ≥0.5 (labeled “Initiating treatment”); and E, cessation of asthma maintenance therapy during the period (labeled “Treatment discontinuation”). Green represents a ratio ≥0.5 (ie, an adequate asthma quality of care), red a ratio <0.5 (ie, an inadequate asthma quality of care), and blue an irregular asthma maintenance therapy (ie, <4 dispensings of ICS or LTRA over a 12-month period). The vertical axis represents the proportion of women in each category. E3N, Etude Epidémiologique auprès de femmes de la Mutuelle Générale de l'Education Nationale; ICS, inhaled corticosteroids; LTRA, leukotriene receptor antagonists.
The Journal of Allergy and Clinical Immunology: In Practice DOI: ( /j.jaip )
Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5. Figure 4
Associations (odds ratio with 95% CI) between the clusters of the controller-to-total medication ratio fluctuations obtained by latent class analysis and poor asthma-related outcomes (uncontrolled asthma, asthma attacks, and asthma exacerbations) among women with ever asthma from the Asthma-E3N study (n = 4,328). Logistic regressions were weighted by the posterior probability of belonging to the cluster. CI, Confidence interval; E3N, Etude Epidémiologique auprès de femmes de la Mutuelle Générale de l'Education Nationale; OR, odds ratio.
The Journal of Allergy and Clinical Immunology: In Practice DOI: ( /j.jaip )
Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6. Figure E1
Study design for the definition of the level of the controller-to-total asthma medication ratio. The level of the controller-to-total asthma medication ratio was estimated from the MGEN drug database in the 12 months that preceded each asthma-related outcome (from month −13 to month −1 for asthma control and the health-related quality of life, and from month −24 to month −12 for asthma attacks and exacerbations, which were reported over the preceding year). AQLQ, Asthma quality of life questionnaire; E3N, Etude Epidémiologique auprès de femmes de la Mutuelle Générale de l'Education Nationale; M, month; MGEN, Mutuelle Générale de l'Education Nationale.
The Journal of Allergy and Clinical Immunology: In Practice DOI: ( /j.jaip )
Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions